- Home
- News
News about CCII and Cancer Immunotherapy
Find out what is happening at CCII and in the field of cancer immunotherapy. Here we share the latest news about research at CCII and the CCII research community and about trends in immunology and cancer research.
Featured News
Spermidine to the Rescue?
Spermidine, a polyamine compound found in ribosomes and living tissues and originally isolated from semen, is an increasingly popular anti-aging supplement. Muna Al-Habsi and her colleagues demonstrate in a new paper published in Science that spermidine can enhance cancer immunotherapy blocking the PD-1 pathway by reversing aging effects in killer T-cells.
All News
-
Call for Applications for CCII’s 2025 Doctoral Program Scholarships
The Call for Applications for CCII's 2025 Doctoral Program Scholarships is now open. Application deadline is January 31st, 2025.
More
-
Opening Ceremony for CCII’s new home, the Bristol Myers Squibb Building
On 12th November 2024, the Opening Ceremony for the newly constructed Bristol Myers Squibb Building, which will serve as the hub for activities of the CCII, will be held.
More
-
1st CCII International Symposium on Immunotherapy and Immunobiology
The 1st CCII International Symposium on Immunotherapy and Immunobiology will take place from 13-15 November at the Bristol Myers Squibb Building, CCII's new research building.
More
-
CCII Director Tasuku Honjo Awarded Honorary Doctor of Medicine Degree from the National Taiwan University
Professor Tasuku Honjo was awarded an Honorary Doctor of Medicine Degree from the National Taiwan University. This award honours Professor Honjo's exceptional achievements. It is the first time that a Japanese was awarded with this prestigious degree.
More
-
Blood Biomarkers Offer New Hope in Predicting Response to Cancer Immunotherapy
More